The Saint-Brieuc prosecutor's office said Friday, April 9, that it had opened an investigation into the causes of death after the death of a 42-year-old man who had received a dose of the AstraZeneca vaccine.
To read also: AstraZeneca: Véran ensures that only "two people in a million" can have "an undesirable effect"
"
An investigation to search for the causes of death is well open
", told AFP the public prosecutor Bertrand Leclerc, confirming information from Ouest-France, and specifying that the autopsy had not yet been carried out .
According to Me Étienne Boittin, family lawyer, the man, who died in Pleumeur-Bodou (Côtes-d'Armor), was vaccinated on March 13 and died on March 22.
"
He was in good health, he had a medical reason which was sufficient to vaccinate him but which was unrelated to the thrombosis which was fatal to him
", declared Me Boittin.
"
I have three cases of death resulting from a thrombosis for which one wonders about the link between the thrombosis and the injection of AstraZeneca
", he added.
Three to four weeks of waiting
According to him, it is necessary to wait between three and four weeks to have a "
precise conclusion
" on the origin of the death after complete medical examinations and analysis of the medical file.
Me Boittin hopes to have the conclusions "
within eight to fifteen days
" on the case of a Nantes medical student who died suddenly at home of a thrombosis on March 18, a few days after an injection of the AstraZeneca vaccine.
Since its authorization, the course of AstraZeneca has been chaotic, with several twists and turns that have damaged the confidence of the general public.
On February 2, just after its authorization, it was first reserved for people under 65 in France, for lack of data on its effectiveness in the elderly.
A month later, its use is extended to all ages.
To read also: AstraZeneca vaccine: doubt settles in the places of injections
Then, in mid-March, the vaccine was suspended a few days after reports in Europe of very rare and very atypical thromboses (blood clots).
The European Medicines Agency (EMA) acknowledged on Wednesday that they were well linked to AstraZeneca.
In the meantime, France had decided on March 19 to inject it only to people over 55 years old, because these thromboses have mainly been observed in younger subjects.
